Cefazolin
Cefazolin (cefazolin) is a small molecule pharmaceutical. Cefazolin was first approved as Ancef on 1982-01-01. It is used to treat bacterial endocarditis, bacterial infections, bacterial pneumonia, bacterial skin diseases, and escherichia coli infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Cefazolin (discontinued: Ancef, Cefazolin, Kefzol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefazolin sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CEFAZOLIN AND DEXTROSE | B. Braun Medical | N-050779 RX | 2000-07-27 | 2 products, RLD, RS |
| CEFAZOLIN IN DEXTROSE | Baxter | N-207131 RX | 2015-08-07 | 3 products, RLD, RS |
| CEFAZOLIN SODIUM | Hikma Pharmaceuticals | N-216109 RX | 2022-10-07 | 2 products, RLD, RS |
| CEFAZOLIN SODIUM | HQ Specialty Pharma | N-211413 RX | 2023-05-08 | 1 products, RLD, RS |
Show 4 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cefazolin | ANDA | 2024-10-16 |
| cefazolin sodium | ANDA | 2024-09-24 |
Indications
FDA
EMA
Show 2 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CEFAZOLIN SODIUM, CEFAZOLIN AND DEXTROSE, B BRAUN | |||
| 2023-11-23 | NPP | ||
Patent Expiration
No data
Clinical
Clinical Trials
243 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 6 | 9 | 16 | 23 | 26 | 77 |
| Communicable diseases | D003141 | — | — | 1 | 5 | 10 | 12 | 16 | 42 |
| Surgical wound infection | D013530 | — | — | 2 | 2 | 6 | 16 | 12 | 36 |
| Wound infection | D014946 | — | — | — | — | 1 | 9 | 6 | 16 |
| Staphylococcal infections | D013203 | — | A49.01 | — | 2 | 3 | 3 | 4 | 12 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | 3 | 3 | 2 | 2 | 10 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | 1 | — | 5 | 1 | 9 |
| Wounds and injuries | D014947 | — | T14.8 | — | 2 | 1 | 3 | 3 | 9 |
| Antibiotic prophylaxis | D019072 | — | — | — | — | 1 | 3 | 5 | 9 |
| Sepsis | D018805 | HP_0100806 | A41.9 | 1 | 3 | 3 | 1 | — | 7 |
Show 72 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial skin diseases | D017192 | — | — | — | 2 | 2 | — | — | 4 |
| Emergencies | D004630 | — | — | — | — | 1 | — | 2 | 3 |
| Keratitis | D007634 | HP_0000491 | H16 | — | — | 1 | — | 2 | 3 |
| Premature rupture fetal membranes | D005322 | HP_0001788 | O42 | — | — | 2 | — | 1 | 3 |
| Rupture | D012421 | — | — | — | — | 2 | — | 1 | 3 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | 1 | 1 | — | 1 | 3 |
| Neoplasms | D009369 | — | C80 | — | — | 1 | — | 1 | 2 |
| Infectious skin diseases | D012874 | — | — | — | — | 1 | — | — | 1 |
| Skin diseases | D012871 | — | L00-L99 | — | — | 1 | — | — | 1 |
| Nephrolithiasis | D053040 | — | N20.0 | — | — | 1 | — | — | 1 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | 1 | — | — | 3 | 4 |
| Critical illness | D016638 | — | — | — | 1 | — | — | 1 | 2 |
| Fever | D005334 | HP_0001945 | R50.9 | — | 1 | — | — | 1 | 2 |
| Endocarditis | D004696 | HP_0100584 | — | — | 1 | — | — | 1 | 2 |
| Randomized controlled trials as topic | D016032 | — | — | 1 | 1 | — | — | — | 1 |
| Precancerous conditions | D011230 | — | — | — | 1 | — | — | — | 1 |
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | 1 | — | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | — | — | 1 | — | — | — | 1 |
| Cross infection | D003428 | — | — | — | 1 | — | — | — | 1 |
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mammaplasty | D016462 | — | — | 1 | — | — | — | 2 | 3 |
| Renal replacement therapy | D017582 | — | — | 1 | — | — | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
| Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
| Cutaneous malignant melanoma | D000096142 | — | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 5 | 5 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | — | — | 3 | 3 |
| Acute cholecystitis | D041881 | EFO_1001289 | K81.0 | — | — | — | — | 3 | 3 |
| Cholecystitis | D002764 | HP_0001082 | K81 | — | — | — | — | 3 | 3 |
| Gallbladder diseases | D005705 | EFO_0003832 | K82.9 | — | — | — | — | 2 | 2 |
| Hysterectomy | D007044 | EFO_0003881 | — | — | — | — | — | 2 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 2 | 2 |
| Closed fractures | D005596 | — | — | — | — | — | — | 2 | 2 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | — | — | 1 | 1 |
Show 70 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cefazolin |
| INN | cefazolin |
| Description | Cefazolin is a first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively. It has a role as an antibacterial drug. It is a cephalosporin, a member of thiadiazoles, a member of tetrazoles and a beta-lactam antibiotic allergen. It is a conjugate acid of a cefazolin(1-). |
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1 |
Identifiers
| PDB | — |
| CAS-ID | 25953-19-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1435 |
| ChEBI ID | 474053 |
| PubChem CID | 33255 |
| DrugBank | DB01327 |
| UNII ID | IHS69L0Y4T (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Cefazolin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 24,760 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,777 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use